While Vor Biopharma Inc has underperformed by -2.48%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VOR fell by -57.73%, with highs and lows ranging from $3.14 to $0.70, whereas the simple moving average fell by -44.00% in the last 200 days.
On July 26, 2022, Wedbush started tracking Vor Biopharma Inc (NASDAQ: VOR) recommending Outperform. A report published by Goldman on April 27, 2022, Initiated its previous ‘Neutral’ rating for VOR. H.C. Wainwright also rated VOR shares as ‘Buy’, setting a target price of $26 on the company’s shares in an initiating report dated December 17, 2021. Robert W. Baird Initiated an Outperform rating on December 03, 2021, and assigned a price target of $38. Oppenheimer initiated its ‘Outperform’ rating for VOR, as published in its report on December 02, 2021. JMP Securities’s report from October 19, 2021 suggests a price prediction of $40 for VOR shares, giving the stock a ‘Mkt Outperform’ rating. B. Riley Securities also rated the stock as ‘Buy’.
Analysis of Vor Biopharma Inc (VOR)
One of the most important indicators of Vor Biopharma Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -78.07% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 6.54, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and VOR is recording 849.66K average volume. On a monthly basis, the volatility of the stock is set at 11.69%, whereas on a weekly basis, it is put at 9.46%, with a loss of -11.87% over the past seven days. Furthermore, long-term investors anticipate a median target price of $13.19, showing growth from the present price of $0.93, which can serve as yet another indication of whether VOR is worth investing in or should be passed over.
How Do You Analyze Vor Biopharma Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.87%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 68.98% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VOR shares are owned by institutional investors to the tune of 68.98% at present.
